That sounds about right...it translates to about $1.80 per share pre-split, which is about where TTNP was before the FDA's materials were released prior to the Ad Comm in 2013. Personally, I think the odds are a lot better this time around, but I think we have to be realistic and realize 99.9% of the investing community has never heard of Titan, and those who have are wary of its significant string of failures..iloperidone, DIPTA, and the debacle after the Ad Com etc.
Personally, I think probuphine will be approved ahead of schedule...2015 is unlikely, but early January 2016 could happen. The Pro-Neura/Ropinrole Phase I/II should commence just as the first probuphine sales numbers are announced...which I believe will beat estimates...so a year from now, with analyst coverage and institutions buying, I think we are above $40.00 a share.
News 
Market Data 
Discover 
